Exploiting defects in homologous recombination repair for metastatic, castration-resistant prostate cancer

被引：2

作者：

Chau, Vincent ^{[1
]}

Madan, Ravi A. ^{[1
]}

Figg, William D. ^{[1
]}

机构：

[1] NIH, Genitourinary Malignancies Branch, Bldg 10, Bethesda, MD 20892 USA

来源：

CANCER BIOLOGY & THERAPY | 2020年 / 21卷 / 10期

关键词：

Homologous recombination; DNA repair; metastatic prostate cancer; olaparib; DOUBLE-STRAND BREAKS; DNA; MUTATIONS; OLAPARIB; ACTIVATION;

D O I：

10.1080/15384047.2020.1809913

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The PROfound trial highlights that there is a benefit in testing genes involved in homologous recombination (HR) and forms the rationale for testing in all patients with metastatic, castration-resistant prostate cancer (mCRPC). This trial also demostrates that olaparib improves progression free survival (PFS), objective response rate (ORR), and time to pain progression in patients who harbor alterations inBRCA1, BRCA2, andATM. These are groundbreaking findings - this is the first trial that demonstrates the efficacy of olaparib versus standard therapy in a genomically-selected patient population with metastatic prostate cancer. Although this trial does not demonstrate improvements in overall survival (OS), we believe that this may be an underestimation based on trial-design. Future studies of olaparib are likely to yield further promising results.

引用

页码：884 / 887

页数：4

共 26 条

[1] Non-BRCA DNA Damage Repair Gene Alterations and Response to the PARP Inhibitor Rucaparib in Metastatic Castration-Resistant Prostate Cancer: Analysis From the Phase II TRITON2 Study [J].

Abida, Wassim ;

Campbell, David ;

Patnaik, Akash ;

Shapiro, Jeremy D. ;

Sautois, Brieuc ;

Vogelzang, Nicholas J. ;

Voog, Eric G. ;

Bryce, Alan H. ;

McDermott, Ray ;

Ricci, Francesco ;

Rowe, Julie ;

Zhang, Jingsong ;

Piulats, Josep Maria ;

Fizazi, Karim ;

Merseburger, Axel S. ;

Higano, Celestia S. ;

Krieger, Laurence E. ;

Ryan, Charles J. ;

Feng, Felix Y. ;

Simmons, Andrew D. ;

Loehr, Andrea ;

Despain, Darrin ;

Dowson, Melanie ;

Green, Foad ;

Watkins, Simon P. ;

Golsorkhi, Tony ;

Chowdhury, Simon .

CLINICAL CANCER RESEARCH, 2020, 26 (11) :2487-2496

[2]

Addenbrooke's Hospital CUHFT, 2014, STUD OL DEG GIV MEN

[3]

Antonarakis E, 2017, OLAPARIB MEN HIGHRIS

[4] A synthetic lethal therapeutic approach: Poly(ADP) ribose polymerase inhibitors for the treatment of cancers deficient in DNA double-strand break repair [J].

Ashworth, Alan .

JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (22) :3785-3790

[5]

AstraZeneca, 2018, STUD OL PLUS AB 1 LI

[6] Germline BRCA Mutations Are Associated With Higher Risk of Nodal Involvement, Distant Metastasis, and Poor Survival Outcomes in Prostate Cancer [J].

Castro, Elena ;

Goh, Chee ;

Olmos, David ;

Saunders, Ed ;

Leongamornlert, Daniel ;

Tymrakiewicz, Malgorzata ;

Mahmud, Nadiya ;

Dadaev, Tokhir ;

Govindasami, Koveela ;

Guy, Michelle ;

Sawyer, Emma ;

Wilkinson, Rosemary ;

Ardern-Jones, Audrey ;

Ellis, Steve ;

Frost, Debra ;

Peock, Susan ;

Evans, D. Gareth ;

Tischkowitz, Marc ;

Cole, Trevor ;

Davidson, Rosemarie ;

Eccles, Diana ;

Brewer, Carole ;

Douglas, Fiona ;

Porteous, Mary E. ;

Donaldson, Alan ;

Dorkins, Huw ;

Izatt, Louise ;

Cook, Jackie ;

Hodgson, Shirley ;

Kennedy, M. John ;

Side, Lucy E. ;

Eason, Jacqueline ;

Murray, Alex ;

Antoniou, Antonis C. ;

Easton, Douglas F. ;

Kote-Jarai, Zsofia ;

Eeles, Rosalind .

JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (14) :1748-+

[7]

Excellence OCo, 2020, FDA GRANTS ACC APPR

[8] Germline BRCA Mutations Denote a Clinicopathologic Subset of Prostate Cancer [J].

Gallagher, David J. ;

Gaudet, Mia M. ;

Pal, Prodipto ;

Kirchhoff, Tomas ;

Balistreri, Lisa ;

Vora, Kinjal ;

Bhatia, Jasmine ;

Stadler, Zsofia ;

Fine, Samson W. ;

Reuter, Victor ;

Zelefsky, Michael ;

Morris, Michael J. ;

Scher, Howard I. ;

Klein, Robert J. ;

Norton, Larry ;

Eastham, James A. ;

Scardino, Peter T. ;

Robson, Mark E. ;

Offit, Kenneth .

CLINICAL CANCER RESEARCH, 2010, 16 (07) :2115-2121

[9] Synthetic Lethality -- A New Direction in Cancer-Drug Development. [J].

Iglehart, J. Dirk ;

Silver, Daniel P. .

NEW ENGLAND JOURNAL OF MEDICINE, 2009, 361 (02) :189-191

[10] Olaparib Monotherapy in Patients With Advanced Cancer and a Germline BRCA1/2 Mutation [J].

Kaufman, Bella ;

Shapira-Frommer, Ronnie ;

Schmutzler, Rita K. ;

Audeh, M. William ;

Friedlander, Michael ;

Balmana, Judith ;

Mitchell, Gillian ;

Fried, Georgeta ;

Stemmer, Salomon M. ;

Hubert, Ayala ;

Rosengarten, Ora ;

Steiner, Mariana ;

Loman, Niklas ;

Bowen, Karin ;

Fielding, Anitra ;

Domchek, Susan M. .

JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (03) :244-250

← 1 2 3 →